OverviewSuggest Edit
ChemoCentryx is a biopharmaceutical company focused on the development and commercialization of medications targeting inflammatory disorders, autoimmune diseases, and cancer. It focuses on orphan and rare diseases, chronic kidney disease, immuno-oncology, and other inflammatory diseases.
| Type | Public | |
| Founded | 1997 | |
| HQ | San Carlos, CA, US | Map |
| Website | chemocentryx.com | |
| Employee Ratings | More |
Recent NewsAll News
- ChemoCentryx Announces Upcoming Conference Abstracts Focused on TAVNEOS® (avacopan) and the Burden of Systemic Glucocorticoid Use in ANCA-Associated Vasculitis
- Thinking about buying stock in Draftkings, ChemoCentryx, Opendoor Technologies, 1life Healthcare, or Enservco Corp?
- ChemoCentryx Reports Pharmacokinetic and Pharmacodynamic Results from Ongoing Phase I Trial of Orally Administered PD-L1 Inhibitor, CCX559, at American Association for Cancer Research (AACR) Annual Meeting 2022
- (CCXI Alert) Should Management be Held Accountable for ChemoCentryx Investors Losses? Contact Johnson Fistel
Key People/Management at ChemoCentryx
Thomas J. Schall
President, Chief Executive Officer and Chairman of the Board
Susan M. Kanaya
Executive Vice President, Chief Financial and Administrative Officer and Secretary
Markus J. Cappel
Chief Business Officer and Treasurer
Dalia R. Rayes
Senior Vice President, Head of Commercial
Rita I. Jain
Executive Vice President, Chief Medical Officer and Director
Sangita Ghosh
Senior Vice President, Technical Operations
ChemoCentryx Office Locations
ChemoCentryx has an office in San Carlos
San Carlos, CA, US (HQ)
835 Industrial Rd #600
ChemoCentryx Financials and Metrics
ChemoCentryx Revenue
ChemoCentryx's revenue was reported to be $64.89 m in FY, 2020 which is a 79.6% increase from the previous period.
| USD | |
|---|---|
Revenue (Q3, 2021) | 17.7m |
Net income (Q3, 2021) | (22.3m) |
EBIT (Q3, 2021) | (21.8m) |
Market capitalization (13-May-2022) | 1.3b |
Closing stock price (13-May-2022) | 19.2 |
Cash (30-Sept-2021) | 93.7m |
EV | 1.3b |
ChemoCentryx's current market capitalization is $1.3 b.
Annual
Quarterly
| USD | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 |
|---|---|---|---|---|---|---|---|---|---|
Revenue | 8.3m | 7.2m | 10.6m | 6.0m | 49.4m | 5.1m | 10.4m | 1.8m | 17.7m |
General and administrative expense | 5.5m | 5.6m | 6.1m | 8.8m | 10.3m | 10.4m | 16.3m | 19.7m | 19.6m |
R&D expense | 15.4m | 17.6m | 18.1m | 19.3m | 18.8m | 18.6m | 23.4m | 20.9m | 19.9m |
Operating expense total | 20.9m | 23.2m | 24.2m | 28.1m | 29.1m | 28.9m | 39.7m | 40.6m | 39.5m |
Annual
Annual
Quarterly
| USD | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 | Q2, 2021 | Q3, 2021 |
|---|---|---|---|---|---|---|---|---|---|
Net Income | (11.9m) | (27.1m) | (40.0m) | (21.7m) | (1.4m) | (25.5m) | (29.7m) | (68.9m) | (91.2m) |
Depreciation and Amortization | 141.0k | 276.0k | 413.0k | 143.0k | 275.0k | 402.0k | 117.0k | 1.1m | 2.1m |
Accounts Payable | 327.0k | 8.0k | (29.0k) | 1.0m | 370.0k | 213.0k | 1.2m | 2.6m | 68.0k |
Cash From Operating Activities | (18.3m) | (33.2m) | (49.9m) | (27.4m) | (45.8m) | (61.9m) | (21.6m) | (39.4m) | (64.7m) |
| USD | FY, 2018 |
|---|---|
Revenue/Employee | 564.1k |
Debt/Equity | 1.3 x |
Debt/Assets | 0.1 x |
Financial Leverage | 12.4 x |
ChemoCentryx Acquisitions / Subsidiaries
| Company Name | Date | Deal Size |
|---|---|---|
| ChemoCentryx Ireland Limited | ||
| ChemoCentryx Limited |
ChemoCentryx Cybersecurity Score
ChemoCentryx Environment, Social & Governance (ESG) Ratings
ChemoCentryx Online and Social Media Presence
669 Twitter followers
ChemoCentryx has 669 Twitter Followers. The number of followers has increased 0.3% month over month and increased 4.3% quarter over quarter
ChemoCentryx's Trends
Twitter Engagement Stats for @chemocentryxinc
118
Tweets
262
Following
669
Followers
4
Tweets last 30 days
5.8
Avg. likes per Tweet
100%
Tweets with engagement
ChemoCentryx News and Updates
May 11, 2022
ChemoCentryx Announces Upcoming Conference Abstracts Focused on TAVNEOS® (avacopan) and the Burden of Systemic Glucocorticoid Use in ANCA-Associated Vasculitis
SAN CARLOS, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced upcoming presentations at three key medical conferences that will highlight findings from the pivotal Phase III ADVOCATE trial that supported the approval of TAVNEOS® (avacopan), an orally admi…
May 06, 2022
Thinking about buying stock in Draftkings, ChemoCentryx, Opendoor Technologies, 1life Healthcare, or Enservco Corp?
NEW YORK, May 6, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DKNG, CCXI, OPEN, ONEM, and ENSV. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
April 13, 2022
ChemoCentryx Reports Pharmacokinetic and Pharmacodynamic Results from Ongoing Phase I Trial of Orally Administered PD-L1 Inhibitor, CCX559, at American Association for Cancer Research (AACR) Annual Meeting 2022
-- Human pharmacokinetics (PK) reveal CCX559 exposure tracking with projections, with good oral availability and expected half-life -- -- Pharmacodynamic (PD) results show CCX559 exhibits immune stimulatory properties in cancer patients --
March 03, 2022
(CCXI Alert) Should Management be Held Accountable for ChemoCentryx Investors Losses? Contact Johnson Fistel
SAN DIEGO, March 02, 2022 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP is investigating potential claims on behalf of ChemoCentryx, Inc. ("ChemoCentryx" or "the Company") (NASDAQ: CCXI) against certain of its officers and directors.
February 23, 2022
ChemoCentryx to Hold Fourth Quarter and Full Year 2021 Financial Results Conference Call on Tuesday, March 1, 2022
MOUNTAIN VIEW, Calif., Feb. 23, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's fourth quarter and full year 2021 financial results will be released after market close on Tuesday, March 1, 2022. ChemoCentryx executive management will host a conferenc…
February 19, 2022
CHEMOCENTRYX INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of ChemoCentryx, Inc. - CCXI
NEW ORLEANS, Feb. 18, 2022 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into ChemoCentryx, Inc. (NasdaqGS: CCXI). On May 4, 2021, the U.S....
ChemoCentryx Blogs
May 16, 2022
ChemoCentryx to Present at the H.C. Wainwright Global Investment Conference
ChemoCentryx to Present at the H.C. Wainwright Global Investment Conference
Content Import
Mon, 05/16/2022 - 08:30
ChemoCentryx to Present at the H.C. Wainwright Global Investment Conference
05/16/22
General
SAN CARLOS, Calif., May 16, 2022 (GLOBE…
May 05, 2022
ChemoCentryx Reports First Quarter 2022 Financial Results and Recent Highlights
-- Five-fold increase in net sales of TAVNEOS ® (avacopan) quarter-over-quarter with $5.4 million in Q1 2022 -- -- Marked growth in key performance indicators (Q1 2022 to Q4 2021 comparison): - 195% TAVNEOS new Patient Start Forms - 275% Unique Prescribers - 308% Patients on Drug -- -- Global
April 28, 2022
ChemoCentryx to Hold First Quarter 2022 Financial Results Conference Call on Thursday, May 5, 2022
ChemoCentryx to Hold First Quarter 2022 Financial Results Conference Call on Thursday, May 5, 2022
Content Import
Thu, 04/28/2022 - 08:30
ChemoCentryx to Hold First Quarter 2022 Financial Results Conference Call on Thursday, May 5, 2022
04/28/22
General
…
March 01, 2022
ChemoCentryx Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights
-- Total revenue of $32.2 million in 2021 with $2.3 million in Q4; TAVNEOS ® (avacopan) US net product sales of approximately $1.0 million in Q4 2021 following US Food and Drug Administration (FDA) approval in ANCA-associated vasculitis -- -- TAVNEOS also approved in European Union (EU) triggering
November 09, 2021
ChemoCentryx Reports Third Quarter 2021 Financial Results and Recent Highlights
-- U.S. Food & Drug Administration (FDA) approves TAVNEOS TM (avacopan) in ANCA-Associated Vasculitis in October -- -- TAVNEOS now launched in the U.S. -- -- TAVNEOS approved also in Japan ; European CHMP opinion expected this month -- -- Pipeline advances: Company intends to meet with FDA on pa…
August 09, 2021
ChemoCentryx Reports Second Quarter 2021 Financial Results and Recent Highlights
-- Company filed an amendment to its NDA for avacopan in the treatment of ANCA-associated vasculitis; PDUFA goal date extended to October 7, 2021 -- -- Applications for regulatory approval of avacopan in ANCA-associated vasculitis also under review by the European Medicines Agency and the Japan
ChemoCentryx Frequently Asked Questions
When was ChemoCentryx founded?
ChemoCentryx was founded in 1997.
Who are ChemoCentryx key executives?
ChemoCentryx's key executives are Thomas J. Schall, Susan M. Kanaya and Markus J. Cappel.
How many employees does ChemoCentryx have?
ChemoCentryx has 133 employees.
What is ChemoCentryx revenue?
Latest ChemoCentryx annual revenue is $64.9 m.
What is ChemoCentryx revenue per employee?
Latest ChemoCentryx revenue per employee is $487.9 k.
Who are ChemoCentryx competitors?
Competitors of ChemoCentryx include Precision Medicines, NOXXON Pharma and Telix Pharmaceuticals.
Where is ChemoCentryx headquarters?
ChemoCentryx headquarters is located at 835 Industrial Rd #600, San Carlos.
Where are ChemoCentryx offices?
ChemoCentryx has an office in San Carlos.
How many offices does ChemoCentryx have?
ChemoCentryx has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies